Back to Search
Start Over
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
- Source :
-
Leukemia & Lymphoma . Dec2011, Vol. 52 Issue 12, p2308-2315. 8p. 4 Charts, 1 Graph. - Publication Year :
- 2011
-
Abstract
- A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered intravenously twice weekly for 2 weeks at 22.5, 45, 90, 150, 225, 300 or 400 mg/m2 followed by 10 days off-treatment was conducted to determine the safety and maximum tolerated dose (MTD) of IPI-504 in patients with relapsed or relapsed/refractory multiple myeloma (MM). Anti-tumor activity and pharmacokinetics were also evaluated. Eighteen patients (mean age 60.5 years; median 9 prior therapies) were enrolled. No dose-limiting toxicities (DLTs) were reported for IPI-504 doses up to 400 mg/m2. The most common treatment-related adverse event was grade 1 infusion site pain (four patients). All other treatment-related events were assessed as grade 1 or 2 in severity. The area under the curve (AUC) increased with increasing dose, and the mean half-life was approximately 2-4 h for IPI-504 and its metabolites. Four patients had stable disease, demonstrating modest single-agent activity in relapsed or relapsed/refractory MM. [ABSTRACT FROM AUTHOR]
- Subjects :
- *MULTIPLE myeloma
*PLASMACYTOMA
*B cell lymphoma
*PHARMACOKINETICS
*PHARMACOLOGY
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 52
- Issue :
- 12
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 67462987
- Full Text :
- https://doi.org/10.3109/10428194.2011.600481